Advertisement
New Zealand markets closed
  • NZX 50

    12,105.29
    +94.63 (+0.79%)
     
  • NZD/USD

    0.5977
    -0.0028 (-0.47%)
     
  • NZD/EUR

    0.5535
    -0.0008 (-0.14%)
     
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • OIL

    83.13
    +1.78 (+2.19%)
     
  • GOLD

    2,240.70
    +28.00 (+1.27%)
     
  • NASDAQ

    18,237.31
    -43.54 (-0.24%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • Dow Jones

    39,757.00
    -3.08 (-0.01%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • NZD/JPY

    90.4000
    -0.3800 (-0.42%)
     

Key Updates on Teva’s Restructuring Plan Progress

Key Updates on Teva’s Restructuring Plan Progress

Investor Update: How Is Teva's Restructuring Plan Progressing? Teva Pharmaceutical (TEVA) announced a restructuring plan in mid-December 2017. The announcement came after the company made some key leadership changes to recuperate from the dismal performance it saw over the last few quarters following its acquisition of Allergan’s (AGN) generics business and the negative impact of increasing generics business competition and pricing pressures.